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Abstract
Four cyclopentenone-containing ansamycin polyketides (mccrearamycins A–D), and six new 
geldanamycins (Gdms B–G, including new linear and mycothiol conjugates), were characterized 
as metabolites of Streptomyces sp. AD-23-14 isolated from the Rock Creek underground coal 
mine acid drainage site. Biomimetic chemical conversion studies using both simple synthetic 
models and Gdm D confirmed that the mccrearamycin cyclopentenone derives from benzilic acid 
rearrangement of 19-hydroxy Gdm, and thereby provides a new synthetic derivatization strategy 
and implicates a potential unique biocatalyst in mccrearamycin cyclopentenone formation. In 
addition to standard Hsp90α binding and cell line cytotoxicity assays, this study also highlights 
the first assessment of Hsp90α modulators in a new axolotl embryo tail regeneration (ETR) assay 
as a potential new whole animal assay for Hsp90 modulator discovery.
Mining for geldanamycins
Six new geldanamycins (Gdms) and four new ring-contracted cyclopentenone macrolactams are 
reported as metabolites of an abandoned Kentucky coal mine-associated microbe. A biosynthetic 
pathway via benzilic acid rearrangement is proposed and an axolotl embryo tail regeneration assay 
is utilized to assess the Hsp90 inhibitory activities of the metabolites.
Keywords
ansamycin; axolotl; biomimetic synthesis; Hsp90; regeneration
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Geldanamycin (Gdm)-type polyketides are prototypical microbial benzoquinone ansamycin 
anticancer agents that target the N-terminal ATP-binding domain of heat shock protein 90 
(Hsp90; Figure 1A).[1] While a number of elegant and efficient Gdm synthetic and 
biosynthetic production and derivatization strategies have been developed,[2] C-17 semi-
synthetic Gdm modification was a key to both first (tanespimycin/17-AAG[3] and orally 
bioavailable alvespimicin/17-DMAG)[4] and second (retaspimycin hydrochloride/IPI-504)[5] 
generation analogues advanced to the clinic (Figure 1A), the latter of which displayed 
improved solubility and reduced hepatotoxicity.[6] More recent medicinal chemistry efforts 
have focused on C-19 substitution to prohibit non-specific alkylation (a putative contributor 
to non-selective toxicity), analogues of which were found to opportunistically favor the cis-
amide conformer observed in the Gdm-Hsp90 ligand-bound complex.[7] As part of a 
microbial natural products discovery effort from coal-mining-associated environments in 
Kentucky, USA,[8] herein we describe the isolation and structure elucidation of six new Gdm 
analogues (1–6), and four unprecedented ring-contracted cyclopentenone macrolactams 
(mccrearamycins A–D, 7–10) from the Rock Creek (McCreary County) underground coal 
mine acid drainage isolate Streptomyces sp. AD-23-14 (Figure 1B). Biomimetic studies 
using both simple synthetic models and isolated Gdm analogues revealed the ortho-quinone 
to undergo a facile benzilic acid rearrangement to provide the ring-contracted 
cyclopentenone scaffold, presenting both a new synthetic strategy and implicating the role of 
a potential novel biocatalyst for ansamycin ring contraction. In addition to expanding 
Hsp90α inhibitor SAR, these studies also highlight the first assessment of Hsp90α 
modulators in a new axolotl (Ambystoma mexicanum) embryo tail regeneration (ETR) 
assay.[9]
Gdms B–G (1–6) were characterized as new Gdm analogues (including mycothiol conjugate 
2 and linear Gdms 5–6) based on NMR, MS, and comparison with literature precedent (see 
Figure 1 and the Supporting Information). While 7–10 also shared the signature spectral 
features of Gdm 19-membered macrolactams (Figures S2–S4), they notably lacked 
indicators of the corresponding Gdm 1,4-benzoquinone. Key HMBC correlations [for 
example, for 7, from a nitrogen-bearing CH (δH = 5.12 ppm, 20-H) to C-16 (δC = 116.2 
ppm), C-17 (δC = 177.0 ppm) and C-18 (δC = 71.1 ppm), and from 18-OH (δH = 6.16 ppm) 
to C-17 and C-18] implicated an unprecedented alternative cyclopentenone ring (Figure 1B) 
in 7–10. Determination of C-18 substitution (MSH in 7; methyl formate in 8–10) relied on 
HMBC correlations (Figures S2 and S3). The relative configurations of 7–10 were 
established through NOESY (Figures S3 and S4) where many observed modifications 
paralleled those of corresponding Gdm analogues. Namely, like 3 (Gdm D), hydration of the 
8 C-4/C-5 double bond was observed, and similar to 6 (Gdm G), 9 and 10 were also 
identified as N-20-acyl (2-hydroxy-acetate) linear metabolites (Tables S1 and S4, Figures 
S2–S4). These cumulative analyses established 7–10 as new ring-contracted cyclopentenone 
macrolactams and thus were named mccrearamycins A–D in reference to the structural 
novelty and the producing strain3s point of origin.
The similarities between Gdms and mccrearamycins from Streptomyces sp. AD-23-14 
implicated Gdms as potential mccrearamycin progenitors (Scheme 1). In addition, while 
NOESY firmly established the cyclopentenone C-18/C-20 relative trans-configuration in 7, 
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the key 1H NMR resonance for 18-OH was lacking for 8–10. For further validation, a model 
study was pursued to assess cyclopentenone formation via ring contraction of a 19-OH Gdm 
progenitor (Scheme 1) reminiscent of the classical cyclohexanone to cyclopentane-1-
carboxylate benzilic acid rearrangement.[10] While the corresponding Gdm rearrangement is 
unprecedented, the analogous Hooker oxidation rearrangement of hydroxynaphthoquinones 
to indane carboxylic acids served as related precedent.[11] For this study, the synthesis of the 
Gdm model surrogate 2-hydroxyquinone 21 (Scheme 2) commenced with aryl lithiation–
alkylation of benzyl methyl ether 12. DDQ-mediated oxidation of 13 followed by hydroxy-
directed iodination provided phenol 15. The iodide was then treated with copper powder in 
basic medium to provide catechol 16, which was selectively methylated by Me2SO4. 
Methoxymethyl protection of the remaining phenolic hydroxyl followed by Baeyer–Villiger 
oxidation produced the key intermediate 18. Consistent with challenges associated with 
hexasubstituted benzene syntheses,[12] amination, amidation, and nitration of 18 directly, or 
of corresponding halogenated derivatives using transition-metal catalysts, failed to give 
desired aniline 19 or amide 20. However, azo coupling with sulfanilic acid,[13] followed by 
dithionite reduction, gave aniline 19 in 62% yield. Sequential acetylation, hydrolysis, 
oxidation, and deprotection furnished template 21 in 73% yield, and methylation of 21 
further afforded the corresponding 2-methoxy quinone 22 as an additional comparator.
Consistent with the impact of CuCl2 on benzilic acid rearrangement stereoselectivity and 
yield,[14] evaluation of the putative 21 benzilic acid rearrangement in the presence of 
transition metal salts and various other known benzilic acid rearrangement promoters 
revealed CoCl2 to afford the best overall yield and stereoselectivity (Table 1). Single-crystal 
X-ray diffraction of the isolated product 23 further established the relative C-2/C-3 trans-
configuration (Table 1 and S7, CCDC 1496415), consistent with the signature 23 2-OH to 3-
CH NOE and corresponding 18-OH to 20-CH NOE of mccrearamycin A (7). A putative 
mechanism for Co2+-assisted benzilic acid rearrangement is depicted in Scheme 1. 
Consistent with this mechanism, the substitution of CH3OH with CD3OD as solvent led to 
selective isotopic label incorporation in 25 (entry 18, Table 1). Importantly, the 2-methoxy 
model 22 and the prototypical Hooker reaction substrate lawsone failed to give the desired 
benzilic acid rearrangement under the optimized conditions (Scheme S1).
To probe the relevance to mccrearamycins, this biomimetic model study was subsequently 
extended to the corresponding 19-hydroxy-substituted Gdm D (3). Remarkably, reaction of 3 
under the same optimized conditions led to 50% conversion to mccrearamycin B (8; entry 
19, Table 1 and Figures S6–S8). The established stereoselectivity of the model reaction 
implicates an 8 cyclopentenone C-18/C-20 trans-configuration identical to that of 7 and 23. 
Comparison of select 13C NMR chemical shifts in mccrearamycins B–D (8–10) to that of 
the trans- and cis-configured models (23 and 24, respectively) provide further support of a 
common benzilic acid rearrangement-derived C-18/C-20 trans-configuration in all of the 
mccrearamycins (Table S5). Subsequent indirect mccrearamycin absolute configuration 
assignment was accomplished through electronic circular dichroism (ECD) analysis. 
Specifically, comparison of the ECD spectra of 8 in MeOH to the theoretical ECD spectra 
[generated using time-dependent density functional theory (TDDFT)][8a,15] for two possible 
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isomers of 8 (8a: 4R, 6S, 7S, 10S, 11R, 12S, 14R, 18S, 20S and 8b: 4R, 6S, 7S, 10S, 11R, 
12S, 14R, 18R, 20R), revealed that of 8a as providing the best spectral match (Figure S9).
Based on the established mechanism of Gdm and related analogues, all of the isolated 
compounds were evaluated in standard Hsp90α inhibition[8b] and cancer cell line (human 
non-small cell lung A549) cytotoxicity assays (Table S7). This cumulative analysis revealed 
the parental prototypes (Gdm, reblastatin, and 17-O-demethyl-reblastatin) to afford greatest 
Hsp90α inhibition (IC50s of 5–30 nM) with notably divergent corresponding cytotoxicities 
(Gdm IC50 1 nM, reblastatin IC50 0.7 μM, and 17-O-demethyl-reblastatin IC50 > 50 μM), 
suggesting the oxidation state and substitution pattern contribute to differences in cellular 
uptake and/or alternative cytotoxicity mechanisms consistent with prior Gdm SAR 
studies.[7a,16] Similar to that of the parental prototypes, the corresponding cytotoxicity of the 
new Streptomyces sp. AD-23-14 metabolites did not correlate with Hsp90α inhibitory 
potential in some cases.
Streptomyces sp. AD-23-14 metabolites were also evaluated using a highly regenerative 
salamander model, the Mexican axolotl (Ambystoma mexicanum).[17] Previous 
transcriptional studies found hsp90aa1 to be significantly upregulated 12 hours after axolotl 
limb and tail amputation, suggesting a role for Hsp90 in tissue regeneration.[9] To investigate 
this further, we used the axolotl embryo tail regeneration (ETR) assay[9b] to test Gdm for an 
inhibitory effect on tail regeneration. Tail-amputated axolotl embryos were incubated in 
microtiter plates in the absence (vehicle control, DMSO) or presence of 10 μM agent (Gdm, 
reblastatin, 7-O-demethyl-reblastatin, and 1–10) and imaged on day 1 (pre-treatment) and 
day 7. An initial single dose screen revealed Gdm to completely inhibit tail regeneration 
with no effect observed for all of the other test agents. Subsequent studies revealed a clear 
dose-response for Gdm, with developmental abnormalities and toxicity observed at the 
highest dose (10 μM), inhibition of regeneration at intermediate doses, and no effect on 
regeneration at the lowest dose (0.1 μM; Figure 2).
In summary, metabolic profiling led to the discovery of new Gdm analogues and a set of 
cyclopentenone macrolactams. The development and implementation of a cobalt-mediated 
benzilic acid rearrangement served as a key feature in mccrearamycin structure validation 
and highlights the potential synthetic utility in the context of 2-hydroxyquinone-containing 
complex natural products. That cyclopentenone formation requires distinct conditions may 
also implicate a unique biosynthetic pathway. These metabolites, together with the parental 
prototypes, also served as a test set to assess the impact of Hsp90 inhibitors in vivo using an 
axolotl ETR assay. While developmental abnormalities have been observed in many 
organisms (including zebrafish administered Gdm[18]) when Hsp90 activity is reduced below 
critical levels,[19] our results demonstrate that Gdm can be administered at a dose that blocks 
regeneration without overtly affecting development. This study implicates Gdm as a useful 
reagent to probe the role of Hsp90 in axolotl tail regeneration and suggests low dose Gdm 
could be used in a sensitized, ETR chemical genetic screen to identify new Hsp90 
modulators.
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Figure 1. 
A) Chemical structures of representative Gdm-type ansamycins and B) new compounds 
isolated from Streptomyces sp. AD-23-14. The unique cyclopentenone ring structure of 
mccrearamycins A–D is highlighted in red.
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Figure 2. 
The impact of [Gdm] on axolotl embryo tail regeneration as determined by the ETR assay 
(*p <0.005, **p <0.0001, n =4; #: 3 axolotls were dead at day 7; A: DMSO control; B: 0.1 
μM; C: 1 μM; D: 2.5 μM; E: 5 μM; F: 10 μM).
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Scheme 1. 
Proposed metal (M2+)-mediated benzilic acid rearrangement of the Gdm hydroxyquinone to 
afford the mccrearamycin cyclopentenone.
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Scheme 2. 
Synthesis of templates 21 and 22.
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